No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses

Affiliations

• ¹ Protein Interactions Group, Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702-12011; dimiter.dimitrov@nih.gov shibojiang@fudan.edu.cn.
• ² Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 20032, China; dimiter.dimitrov@nih.gov shibojiang@fudan.edu.cn.
• ³ Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 20032, China;
• ⁴ Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555;
• ⁵ Comprehensive AIDS Research Center, Research Center for Public Health, School of Medicine, Tsinghua University, Beijing 100084, China;
• ⁶ State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Research Centre of Infection and Immunology, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region of the People's Republic of China.